1994
DOI: 10.1016/0960-0760(94)90151-1
|View full text |Cite
|
Sign up to set email alerts
|

Endocrine properties of the testosterone 5α-reductase inhibitor turosteride (FCE 26073)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
23
0
1

Year Published

1996
1996
2014
2014

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 39 publications
(24 citation statements)
references
References 25 publications
0
23
0
1
Order By: Relevance
“…Finasteride [7l and other highly specific 5a-reductase inhibitors such as epristeride [8] and turosteride [9] have been recently developed on the premise that the 5a-reduced testosterone metabolite, dihydrotestosterone (DHT), is needed for prostate growth. Androgens do regulate some prostate growth factors [16,17], but there is no sound consistent evidence for higher DHT levels in hyperplastic compared to normal tissue when samples are obtained under physiological conditions (18,191.…”
Section: Introductionmentioning
confidence: 99%
“…Finasteride [7l and other highly specific 5a-reductase inhibitors such as epristeride [8] and turosteride [9] have been recently developed on the premise that the 5a-reduced testosterone metabolite, dihydrotestosterone (DHT), is needed for prostate growth. Androgens do regulate some prostate growth factors [16,17], but there is no sound consistent evidence for higher DHT levels in hyperplastic compared to normal tissue when samples are obtained under physiological conditions (18,191.…”
Section: Introductionmentioning
confidence: 99%
“…When tested on rat and human prostatic 5␣-reductases, the compound showed a similar degree of potency with IC 50 values of 53 and 55 nM, respectively [3,4]. Twenty-day oral administration of turosteride to adult male rats at doses of 3, 10, or 30 mg/ kg/day was found to cause a reduction in prostate weight associated with a reduction of prostatic DHT content by 61, 74, and 78%, respectively, without any relevant increase in prostatic T content [5].…”
Section: Introductionmentioning
confidence: 82%
“…Genel olarak hafif-orta derecede şikayeti olan hastalarda, opere edilemeyen hastalarda veya cerrahiyi kabul etmeyen hastalarda medikal tedavi ön plana çıkmaktadır. Medikal tedaviler arasında en çok kullanılan ilaçlar selektif α-blokerler, 5-α redüktaz inhibitörleri, kombine tedaviler ve fitoterapötik ajanlardır (8)(9)(10)(11). Selektif α-blokerler günümüzde en çok kullanılan ajanlardır ve plaseboya üstünlükleri de kanıtlanmıştır (12)(13)(14).…”
Section: Discussionunclassified